It's too early to say. They have only just started dosing the first healthy volunteers*. We don't know about the biodistribution of the tLNP or if it is able to modify only CD8-expressing T-cells in humans.
Even if it modifies only CD8-expressing T-cells, the T-cells will transiently express the CAR. The next question is do the T-cells in the primary, secondary, and/or tertiary tissues express the CAR long enough (and expand) to enable the required B-cell depletion to induce an 'immune reset.'
As for FT819, we could know in Oct (or Dec) if a registrational trial will happen.
Market Data 
Markets 
AI
